Statements (30)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvalYear |
2014
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
N05CM17
|
| gptkbp:contraindication |
narcolepsy
|
| gptkbp:drugClass |
gptkb:orexin_receptor_antagonist
|
| gptkbp:eliminatedIn |
urine
feces |
| gptkbp:form |
gptkb:tablet
|
| gptkbp:genericName |
gptkb:suvorexant
|
| gptkbp:halfLife |
about 12 hours
|
| gptkbp:indication |
treatment of sleep onset and/or sleep maintenance insomnia
|
| gptkbp:legalStatus |
Schedule IV (US)
|
| gptkbp:manufacturer |
gptkb:Merck_&_Co.
|
| gptkbp:marketedAs |
gptkb:United_States
|
| gptkbp:mechanismOfAction |
gptkb:orexin_receptor_antagonist
|
| gptkbp:metabolism |
gptkb:liver_(CYP3A)
|
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:prescriptionStatus |
prescription only
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
headache
dry mouth somnolence abnormal dreams daytime drowsiness |
| gptkbp:usedFor |
insomnia
|
| gptkbp:bfsParent |
gptkb:MRK
gptkb:347396-82-1 |
| gptkbp:bfsLayer |
7
|
| https://www.w3.org/2000/01/rdf-schema#label |
Belsomra
|